AMARQ Financials 07/16/2014 06:39:38 Amarillo Bio

AMARQ Financials 07/16/2014 06:39:38
Amarillo Biosciences, Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue - 1 58 5
Cost of Revenue - - 4 3
Gross Profit - - 54 2
Operating Expenses
Research and Development 133 200 281 433
Sales, General and Admin. 433 355 919 638
Non-Recurring Items - - - -
Other - - - -
Operating Income (566) (555) (1,146) (1,069)
Income From Continuing Operations
Add'l Income/Expense Items 47 59 44 1,670
Earnings Before Interest and Tax (562) (495) (1,102) 600
Interest Expense 103 156 212 94
Earnings Before Tax (665) (651) (1,314) 506
Income Tax - - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (623) (651) (1,314) 506
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (623) (651) (1,314) 506
Preferred Stock and Other Adjustments (32) (31) (17) (4)
Net Income Applicable to Common Shareholders (655) (682) (1,331) 502